Potensi Ekstrak Etanol (96%) Jahe Merah (Zingiber Officinale Var. Rubrum) dalam Memperbaiki Fungsi Hormon, Ovarium dan Resistensi Insulin pada Tikus Wistar Model Polycystic Ovarian Syndrome
DOI:
https://doi.org/10.62383/ikg.v1i4.967Keywords:
Red Ginger Ethanol Extract, Polycystic Ovarian Syndrome (PCOS), Insulin Resistance and Ovarian FunctionAbstract
Previous studies have shown that red ginger has the potential to treat PCOS because it has been proven to be able to reduce serum FSH, LH and estradiol and testosterone, inhibit the cyclooxygenase pathway, change the pituitary axis, inhibit lipoxygenase expression in various animal studies. The purpose of this study is to prove the potential of red ginger extract as a regulator of anti-androgenic, ovulation, estrogenic activity and reduce insulin resistance. The research design used was for experimental research using a post-test-only control group design. And for the analysis of the potential bioactivity of red ginger extract as an immunomodulatory agent computationally (Insilico). Animal care was carried out in the Pharmacology and Biomedicine Laboratory and has received approval from the Ethics Committee. The sample used was a female Wistar rat on the 56th day of the experiment (after modeling). All treatments were given orally for 28 times. Independent variable = Red ginger extract. Dependent variable = Dependent variables are 1. Hormones: Testosterone, LH, FSH 2. ovarian inflammation activation (PPARγ activation and anti-inflammatory cytokines IL-4 and ROS, NFKB, TNF a. 3. Insulin resistance (insulin, glucose, HOMA IR) and 4 Lipid profile (TG, HDL, LDL, cholesterol). Control variables are: 1) Gender; 2) Age; 3) Strain; 4) Food and beverage intake; 5) Maintenance and care. Quantitative and qualitative research data. using parametric tests, namely One-Way ANOVA after meeting the requirements for normal data distribution and the same data variance. The One-Way ANOVA statistical test is continued with the Tuckey test to determine the differences in each group.
References
Abbott, D.H. et al. (2020) ‘Implications for Pathophysiology and Therapy’, 14(2), pp. 131–143. Available at: https://doi.org/10.1080/17446651.2019.1576522.Hyperandrogenic.
Abdalla, M.A. et al. (2020) ‘A review of therapeutic options for managing the metabolic aspects of polycystic ovary syndrome’, Therapeutic Advances in Endocrinology and Metabolism, 11, pp. 1–19. Available at: https://doi.org/10.1177/2042018820938305.
Akre, S. et al. (2022) ‘Recent Advances in the Management of Polycystic Ovary Syndrome: A Review Article’, Cureus, 14(8), pp. 10–15. Available at: https://doi.org/10.7759/cureus.27689.
Aquino, C.I. and Nori, S.L. (2014) ‘Complementary therapy in polycystic ovary syndrome.’, Translational medicine @ UniSa, 9(11), pp. 56–65. Available at: http://www.ncbi.nlm.nih.gov/pubmed/24809037%0Ahttp://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC4012377.
Bannister, C.A. et al. (2014) ‘Can people with type 2 diabetes live longer than those without? A comparison of mortality in people initiated with metformin or sulphonylurea monotherapy and matched, non-diabetic controls’, Diabetes, Obesity and Metabolism, 16(11), pp. 1165–1173. Available at: https://doi.org/10.1111/dom.12354.
Chen, L. et al. (2022) ‘Absorption, metabolism and bioavailability of flavonoids: a review’, Critical Reviews in Food Science and Nutrition, 62(28), pp. 7730–7742. Available at: https://doi.org/10.1080/10408398.2021.1917508.
Dastgheib, M. et al. (2022) ‘A comparison of the effects of cinnamon, ginger, and metformin consumption on metabolic health, anthropometric indices, and sexual hormone levels in women with poly cystic ovary syndrome: A randomized double-blinded placebo-controlled clinical trial’, Frontiers in Nutrition, 9(November), pp. 1–11. Available at: https://doi.org/10.3389/fnut.2022.1071515.
Diamanti-Kandarakis, E. et al. (2010) ‘Metformin: An old medication of new fashion: Evolving new molecular mechanisms and clinical implications in polycystic ovary syndrome’, European Journal of Endocrinology, 162(2), pp. 193–212. Available at: https://doi.org/10.1530/EJE-09-0733.
Diamanti-Kandarakis, E. and Dunaif, A. (2012) ‘Insulin resistance and the polycystic ovary syndrome revisited: An update on mechanisms and implications’, Endocrine Reviews, 33(6), pp. 981–1030. Available at: https://doi.org/10.1210/er.2011-1034.
E, D.-K. et al. (2006) ‘Polycystic ovary syndrome: the influence of environmental and genetic factors.’, Hormones (Athens), 5(1), pp. 17–34.
Echiburú, B. et al. (2012) ‘CAG repeat polymorphism of androgen receptor gene and X-chromosome inactivation in daughters of women with polycystic ovary syndrome (PCOS): Relationship with endocrine and metabolic parameters’, Gynecological Endocrinology, 28(7), pp. 516–520. Available at: https://doi.org/10.3109/09513590.2011.650744.
Gandini, S. et al. (2014) ‘Metformin and cancer risk and mortality: A systematic review and meta-analysis taking into account biases and confounders’, Cancer Prevention Research, 7(9), pp. 867–885. Available at: https://doi.org/10.1158/1940-6207.CAPR-13-0424.
Glintborg, D. et al. (2018) ‘Cardiovascular disease in a nationwide population of Danish women with polycystic ovary syndrome’, Cardiovascular Diabetology, 17(1), pp. 1–12. Available at: https://doi.org/10.1186/s12933-018-0680-5.
Hajam, Y.A. et al. (2024) ‘A review on critical appraisal and pathogenesis of polycystic ovarian syndrome’, Endocrine and Metabolic Science, 14(January), p. 100162. Available at: https://doi.org/10.1016/j.endmts.2024.100162.
Harmanci, A. et al. (2013) ‘Oral contraceptive plus antiandrogen therapy and cardiometabolic risk in polycystic ovary syndrome’, Clinical Endocrinology, 78(1), pp. 120–125. Available at: https://doi.org/10.1111/j.1365-2265.2012.04466.x.
Jones, G.L. et al. (2010) ‘Do South Asian women with PCOS have poorer health-related quality of life than Caucasian women with PCOS? A comparative cross-sectional study’, Health and Quality of Life Outcomes, 8(1), p. 149. Available at: https://doi.org/10.1186/1477-7525-8-149.
Jones, L. and Regan, F. (2019) Endocrine disrupting chemicals. Third Edit, Encyclopedia of Analytical Science. Third Edit. Elsevier. Available at: https://doi.org/10.1016/B978-0-12-409547-2.14512-3.
Kahal, H. et al. (2017) ‘The Prevalence of Polycystic Ovary Syndrome: a Systematic Review and Meta-analysis’, Endocrine Abstracts, 8(56), pp. 96351–96358. Available at: https://doi.org/10.1530/endoabs.50.p339.
Mallick, S., Khatun, S. and Islam, S. (2018) ‘Dyslipidemia in Women with Polycystic Ovary Syndrome : Comparison between Obese Cases and Obese Controls in a Government Hospital in West Bengal’, 6(4), pp. 34–38. Available at: https://doi.org/10.17354/ijss/2018/201.
Mao, Q.Q. et al. (2019) ‘Bioactive compounds and bioactivities of ginger (zingiber officinale roscoe)’, Foods, 8(6), pp. 1–21. Available at: https://doi.org/10.3390/foods8060185.
Mudrikatin, S. (2020) ‘The influence of red ginger extract in menopouse climacterium period of total cholesterols in covid-19 pandemic period in east java’, Systematic Reviews in Pharmacy, 11(6), pp. 831–835. Available at: https://doi.org/10.31838/srp.2020.6.120.
Ollila, M.M.E. et al. (2017) ‘Overweight and obese but not normal weight women with PCOS are at increased risk of Type 2 diabetes mellitus - A prospective, population-based cohort study’, Human Reproduction, 32(2), pp. 423–431. Available at: https://doi.org/10.1093/humrep/dew329.
Osibogun, O., Ogunmoroti, O. and Michos, E.D. (2020) ‘Polycystic ovary syndrome and cardiometabolic risk: Opportunities for cardiovascular disease prevention’, Trends in Cardiovascular Medicine, 30(7), pp. 399–404. Available at: https://doi.org/10.1016/j.tcm.2019.08.010.
Pangastuti, N.P. and Sumapradja, K. (2011) ‘Profile of Policystic Ovarian Syndrome Patients in Dr. Cipto Mangunkusumo General Hospital Jakarta’, Indonesian Journal of Obstetrics and Gynecology, pp. 8–13. Available at: http://inajog.com/index.php/journal/article/view/215.
Patel, R. and Shah, G. (2017) ‘Effect of metformin on clinical, metabolic and endocrine outcomes in women with polycystic ovary syndrome: a meta-analysis of randomized controlled trials’, Current Medical Research and Opinion, 33(9), pp. 1545–1557. Available at: https://doi.org/10.1080/03007995.2017.1279597.
Rubin, K.H. et al. (2017) ‘Development and risk factors of type 2 diabetes in a nationwide population of women with polycystic ovary syndrome’, Journal of Clinical Endocrinology and Metabolism, 102(10), pp. 3848–3857. Available at: https://doi.org/10.1210/jc.2017-01354.
Strowitzki, T. (2021) ‘Advanced diagnosis of polycystic ovary syndrome—new prediction models with standard parameters’, Fertility and Sterility, 115(1), pp. 92–93. Available at: https://doi.org/10.1016/j.fertnstert.2020.09.031.
Sun, C. et al. (2020) ‘Dietary polyphenols as antidiabetic agents: Advances and opportunities’, Food Frontiers, 1(1), pp. 18–44. Available at: https://doi.org/10.1002/fft2.15.
Teng, H. and Chen, L. (2017) ‘α-Glucosidase and α-amylase inhibitors from seed oil: A review of liposoluble substance to treat diabetes’, Critical Reviews in Food Science and Nutrition, 57(16), pp. 3438–3448. Available at: https://doi.org/10.1080/10408398.2015.1129309.
Vink, J.M. et al. (2006) ‘Heritability of polycystic ovary syndrome in a Dutch twin-family study’, Journal of Clinical Endocrinology and Metabolism, 91(6), pp. 2100–2104. Available at: https://doi.org/10.1210/jc.2005-1494.
Williamson, E.M. (2001) ‘1-s2.0-S0944711304700586-main’, 8(5), pp. 401–409. Available at: http://www.urbanfischer.de/journals/phytomed%0APhytomedicine.
Zhao, L. et al. (2016) ‘Polycystic ovary syndrome (PCOS) and the risk of coronary heart disease (CHD): A meta-analysis’, Oncotarget, 7(23), pp. 33715–33721. Available at: https://doi.org/10.18632/oncotarget.9553.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Inovasi Kesehatan Global
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
